Adaptive Pharmacogenomics, LLC

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials.

Cancer Chemother Pharmacol. 2010 May 21;

Authors: Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ

PURPOSE: Monozygotic twins provide an excellent tool to study environmental effects on human health.

Psychiatr Clin North Am. 2010 Mar;33(1):181-224

Authors: Zandi PP, Judy JT

Existing psychotropic medications for the treatment of mental illnesses, including antidepressants, mood stabilizers, and antipsychotics, are clinically suboptimal. They are effective in only a subset of patients or produce partial responses, and they are often associated with debilitating side effects that discourage adherence.

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.

Am J Psychiatry.

Kathmandu Univ Med J (KUMJ). 2009 Apr-Jun;7(26):172-6

Authors: Suvarna BS

Individuals respond differently to drugs and sometimes the effects are unpredictable. Differences in DNA that alter the expression or function of proteins targeted by drugs can contribute significantly to the variation in the individuals responses.

Researchers at the Wayne State University School of Medicine have collectively secured more than $15 million in grants under the American Recovery and Reinvestment Act, the national economic stimulus package signed into law by President Barack Obama.

In total, School of Medicine researchers to date have won $15,136,820 in National Institutes of Health grants through the ARRA. The grants include:

Robert Atkins, Ph. D.

Aliment Pharmacol Ther. 2010 Jan;31(1):11-9

Authors: Rao AS, Camilleri M

BACKGROUND: Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long-term or high-dose use of this medication because of the risk of developing tardive dyskinesia.

Clin Ther. 2010;32 Suppl 1:S3-20

Authors: Stip E, Tourjman V

BACKGROUND: During the past decade, there has been some progress in the pharmacotherapy of schizophrenia and schizoaffective disorder. Current evidence supports the use of various second-generation, or atypical, antipsychotic medications, although few of these agents have been associated with long-term efficacy and tolerability.

QJM. 2009 Nov;102(11):757-72

Authors: Knight JC

Scientific and technological advances in our understanding of the nature and consequences of human genetic variation are now allowing genetic determinants of susceptibility to common multifactorial diseases to be defined, as well as our individual response to therapy.

Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies.

Curr Pharm Des. 2010 May 12;

Authors: Mountzios G, Sanoudou D, Syrigos KN

Even though treatment of several types of solid tumors has improved in the past few years with the introduction of molecular targeted agents in the therapeutic armamentarium of the medical oncologist, response rates to these agents are generally modest.